AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34229502
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment group (Group 2)
Trial: 33084773
Drug: Oral cryotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cryotherapy during the infusion of 5-FU
Trial: 33021877
Drug: Social and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social and Behaviour Change Communication intervention (weekly radio programming, listening and discussion groups, community engagement)
Trial: 33098800
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (systolic blood pressure goal of less than 140 mm Hg)
Trial: 34638151
Drug: Therapeutic-dose bemiparin
RxNorm normalized name: bemiparin
DrugBank: Bemiparin (DB09258)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapeutic-dose bemiparin (115 IU/kg daily)
Trial: 34638151
Drug: Standard prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prophylactic dose (bemiparin 3,500 IU daily)
Trial: 34638151
Drug: Therapeutic-dose bemiparin
RxNorm normalized name: bemiparin
DrugBank: Bemiparin (DB09258)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapeutic-dose bemiparin
Trial: 34638151
Drug: Standard prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prophylactic dose
Trial: 32738875
Drug: Topical citicoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical citicoline and vitamin B12 (Cit‐B12) 3 times daily for 18 months
Trial: 32738875
Drug: Placebo 3
RxNorm normalized name: placebo 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3 times daily for 18 months
Trial: 34898320
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (16 mg IV daily for 5 days followed by 8 mg daily for 5 days)
Trial: 34898320
Drug: Low-dose dexamethasone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexamethasone (6 mg IV daily for 10 days)
Trial: 36375083
Drug: Transurethral irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral irrigation with 0.01% lidocaine (100 mg in 1 L normal saline)
Trial: 35841410
Drug: PBO +
RxNorm normalized name: INV-CIRB#20-18 (PREVENTABLE) ATORVASTATIN 40MG/PBO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBO + ERL (placebo with erlotinib 150 mg/day)
Trial: 34184772
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg litoxetine
Trial: 34184772
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg litoxetine
Trial: 34184772
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg litoxetine
Trial: 34184772
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg litoxetine
Trial: 32825977
Drug: Fateh technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fateh technique (16-min soft tissue manipulation for four weekly sessions)
Trial: 32825977
Drug: Home exercise
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home exercise (two daily exercises for four weeks)
Trial: 33690238
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with tamsulosin, dutasteride, and imidafenacin (TDI)
Trial: 32493475
Drug: Melatonin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (2 mg orally before bedtime for 12 weeks)
Trial: 34699040
Drug: Routine Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine Standard Treatment with Vitamin C
Trial: 34699040
Drug: Routine Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine Standard Treatment with Alpha Lipoic Acid (ALA)
Trial: 34699040
Drug: Routine Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine Standard Treatment with Vitamin C and Alpha Lipoic Acid (ALA)
Trial: 34699040
Drug: Routine Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine Standard Treatment (RST)
Trial: 32970395
Drug: EDS‐FLU 372
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDS‐FLU 372 μg
Trial: 32970395
Drug: EDS‐FLU 186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDS‐FLU 186 μg
Trial: 32970395
Drug: Standard nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nasal steroid sprays
Trial: 34411297
Drug: Clinical treatment
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical treatment network analysis
Trial: 32571560
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants (DOA)
Trial: 32068510
Drug: alfaxalone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfaxalone (5 mg/kg) and midazolam (0.5 mg/kg)
Trial: 32068510
Drug: dexmedetomidine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexmedetomidine (0.05 mg/kg) and midazolam (0.5 mg/kg)
Trial: 32068510
Drug: flumazenil (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flumazenil (0.05 mg/kg) alone or in combination with atipamezole (0.5 mg/kg)
Trial: 35247264
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine (n = 1008)
Trial: 34651239
Drug: Subcutaneous wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous wound irrigation with 0.04% polyhexanide
Trial: 34651239
Drug: Subcutaneous wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous wound irrigation with 0.9% saline
Trial: 34914889
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg intravenously every 2 weeks)
Trial: 36066977
Drug: Exenatide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (2 mg subcutaneously) once weekly for 26 weeks
Trial: 36066977
Drug: Exenatide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (2 mg subcutaneously) once weekly for 26 weeks in a subgroup of obese patients
Trial: 33009192
Drug: TCI‐PCA with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCI‐PCA with target plasma concentrations between 0.8 and 10 ng/ml
Trial: 33009192
Drug: PCA with
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA with bolus doses of 0.2 mg
Trial: 36096886
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic field (PEMF) treatment during the postoperative period
Trial: 34120336
Drug: Gabapentin (3600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (3600 mg/day)
Trial: 34427047
Drug: Family-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused therapy for clinical high risk youth (FFT-CHR) - 18 1-hour sessions of family psychoeducation and communication/problem-solving skills training
Trial: 36066501
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BTA) injections, 50 units into both hands
Trial: 36066501
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections into both hands
Trial: 33839787
Drug: Amlodipine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (maximum 20 mg)
Trial: 33839787
Drug: Prazosin GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin GITS (maximum 30 mg)
Trial: 32138661
Drug: 25 mg/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/L GO
Trial: 32138661
Drug: IAA (>
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAA (> 0.5 mg/L)
Trial: 32138661
Drug: GO treatment
RxNorm normalized name: Go-dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GO treatment
Trial: 34210187
Drug: Distraction condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distraction condition (distracting concurrent task)
Trial: 35970681
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl patches (TFP)
Trial: 35970681
Drug: Non-opioid analgesics
RxNorm normalized name: Non-opioid analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-opioid analgesics (NSAIDs)
Trial: 36141665
Drug: Integrated Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Program for Early Childhood Development (comprehensive early development interventions via bi-weekly home visiting activities and monthly family group activities)
Trial: 34189864
Drug: Moxibustion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion treatment for 8 weeks
Trial: 34189864
Drug: Sham moxibustion
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham moxibustion treatment for 8 weeks
Trial: 35017774
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of dexmedetomidine
Trial: 35017774
Drug: Late administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late administration of dexmedetomidine
Trial: 34910080
Drug: Multifaceted prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted prevention intervention including structured delirium education, daily assessment of delirium risk factors, and tailored prevention strategies (cognitive, motor, sensory stimulation, etc.)
Trial: 38568107
Drug: Etidronate treatment
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etidronate treatment
Trial: 34913487
Drug: Multiple Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Family Therapy (MFT) for 3 months
Trial: 32572020
Drug: 40IU self‐administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40IU self‐administered intranasal oxytocin (OT)
Trial: 35157053
Drug: Early Treatment
RxNorm normalized name: Clearly It!
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early Treatment Study (remote trial)
Trial: 32163509
Drug: Basic Body
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic Body Awareness Therapy (BBAT) plus Treatment as Usual (TAU)
Trial: 32163509
Drug: Mixed Physical
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed Physical Activity (MPA) plus Treatment as Usual (TAU)
Trial: 32449418
Drug: Topical clobetasol
RxNorm normalized name: clobetasol Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clobetasol plus oral low dose naltrexone (3 mg)
Trial: 32449418
Drug: Topical clobetasol
RxNorm normalized name: clobetasol Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clobetasol plus placebo
Trial: 32449418
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose naltrexone (3 mg)
Trial: 33771664
Drug: Ipilimumab and
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab and Nivolumab (combined therapy)
Trial: 35872584
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Isoniazid 15 mg/kg and rifapentine 750/900 mg weekly for 8 weeks.
Trial: 35872584
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Isoniazid [600-(50-body weight)×15] (rounded up) and rifapentine 600/450 mg twice a week for 6 weeks.
Trial: 35559249
Drug: Echinacea purpurea
RxNorm normalized name: Echinacea purpurea
DrugBank: Echinacea purpurea (DB14239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea purpurea extract (Echinaforce®, EF) 2,400 mg daily during prevention cycles
Trial: 32473649
Drug: Lidocaine +
RxNorm normalized name: Lidocaine + Menthol Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine + Propofol (L + P)
Trial: 36135037
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training during AC taper week
Trial: 34915907
Drug: Comparable serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparable serum concentrations of thyroid hormones and binding proteins between patients and controls
Trial: 34915907
Drug: Comparable concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparable concentrations of growth hormone, IGF-I, and IGFBP1 between patients and controls
Trial: 36407843
Drug: Oxycodone/Naloxone Prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/Naloxone Prolonged Release (OXN PR)
Trial: 36407843
Drug: Oxycodone Prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone Prolonged Release (Oxy PR)
Trial: 33075179
Drug: L-arginine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (100 mg/kg TID)
Trial: 32493211
Drug: Modified dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified dose of 0.5% isobaric bupivacaine in group U
Trial: 32493211
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 0.5% isobaric bupivacaine in group C
Trial: 36015163
Drug: Kan Jang®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kan Jang® (daily dose of andrographolides—90 mg)
Trial: 33741696
Drug: Response to
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response to treatment at different diagnostic thresholds of maternal glycemia
Trial: 34469857
Drug: Adjunctive Reading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive Reading Material (ARM)
Trial: 34349181
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium intake (mean 24-h sodium excretion of 3834 mg)
Trial: 32878606
Drug: Injection time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection time < 180 s
Trial: 32878606
Drug: Injection time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection time 180-300 s
Trial: 32878606
Drug: Injection time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection time > 300 s
Trial: 33667460
Drug: Continuous Serratus
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Serratus Anterior Plane Block (SAPB) in combination with intravenous flurbiprofen
Trial: 33667460
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia (Control)
Trial: 32197933
Drug: Intravesical hyaluronic
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravesical hyaluronic acid (HA) 40 mg (Hyacyst®) weekly for 4 weeks, then monthly for 3 months
Trial: 35810525
Drug: Laughter yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laughter yoga (8 sessions over 4 weeks, twice a week)
Trial: 34840600
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy (10 units per 10 cm² of wound, injected in 1 mL 0.9% saline)
Trial: 34403911
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 intravenously on day 1 every 21 days
Trial: 34403911
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 intravenously on day 1 plus erlotinib 150 mg/day orally on day 2-16 every 21 days
Trial: 33315586
Drug: High volume
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High volume injection without corticosteroids (50 mL saline and lidocaine)
Trial: 33315586
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (2 mL saline and lidocaine)
Trial: 33315586
Drug: High volume
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High volume injection without corticosteroids
Trial: 34668986
Drug: Melatonin 10
RxNorm normalized name: melatonin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 10 mg daily during menstruation
Trial: 37148497
Drug: Antimuscarinic agents
RxNorm normalized name: ANTIMUSCARINICS/ANTISPASMODICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimuscarinic agents
Trial: 35685657
Drug: Pulsed Radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Radiofrequency (RF) therapy
Trial: 35685657
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BoNT-A) injection
Trial: 35130966
Drug: Action observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Action observation therapy (AOT) group observing videos of eccentric exercises prior to performing the exercises.
Trial: 35752215
Drug: Age-appropriate intervention
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Age-appropriate intervention consisting of problem-solving therapy, behavioral activation, parenting skills training, and parenting support from a self-identified adult
Trial: 33305660
Drug: Ticagrelor monotherapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor monotherapy (TIC)
Trial: 33305660
Drug: Ticagrelor and
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor and Aspirin (TIC+ASP)
Trial: 34627141
Drug: concomitant medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: concomitant medication
Trial: 32106225
Drug: Housing First
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Housing First treatment (rent supplements and mental health support services)
Trial: 32199021
Drug: Balneotherapy (BT)
RxNorm normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balneotherapy (BT) plus Physical Therapy (PT)
Trial: 36075595
Drug: Chicken‐claw needling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chicken‐claw needling at Xiaguan (ST 7) combined with intradermal needling, once a day for 6 days, total of 2 courses.
Trial: 36075595
Drug: Oral carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral carbamazepine tablets for 13 days.
Trial: 36730056
Drug: Tilavonemab 2000
RxNorm normalized name: Tilavonemab
DrugBank: Tilavonemab (DB17014)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilavonemab 2000 mg
Trial: 33609476
Drug: Tilavonemab 4000
RxNorm normalized name: Tilavonemab
DrugBank: Tilavonemab (DB17014)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilavonemab 4000 mg
Trial: 36297495
Drug: ADV6209 (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADV6209 (0.25 mg kg−1)
Trial: 36297495
Drug: Conventional midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional midazolam (0.25 mg kg−1)
Trial: 34486319
Drug: Wheat bran
RxNorm normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat bran (40 g per day for 30 days)
Trial: 32366796
Drug: PBMT (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBMT (all doses)
Trial: 32040542
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of herbal medicines in active labour
Trial: 32505383
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg linzagolix
Trial: 32505383
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg linzagolix
Trial: 32505383
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg linzagolix
Trial: 32505383
Drug: linzagolix (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linzagolix (doses ≥ 75 mg)
Trial: 33068345
Drug: Oryzanol tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oryzanol tablets and compound vitamin B tablets, 2 tablets each, 3 times daily for 30 days.
Trial: 35863457
Drug: Fluconazole (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (3 sequential 150 mg doses every 72 hours)
Trial: 33876875
Drug: L-citrulline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-citrulline (3 g/day)
Trial: 35005777
Drug: Oral drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drug treatment
Trial: 35363054
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment arms (AHCL and 670G)
Trial: 34103898
Drug: DA-8031 20
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DA-8031 20 mg
Trial: 34103898
Drug: DA-8031 30
RxNorm normalized name: DA-8031
DrugBank: DA-8031 (DB19024)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-8031 30 mg
Trial: 34103898
Drug: DA-8031 40
RxNorm normalized name: DA-8031
DrugBank: DA-8031 (DB19024)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-8031 40 mg
Trial: 35263755
Drug: Once-weekly lonapegsomatropin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly lonapegsomatropin 0.24 mg human growth hormone/kg/week